|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-6-11
|
|
pubmed:abstractText |
We report a patient with AH amyloidosis associated with lymphoplasmacytic leukemia that has remained in a stable state with a nephrotic syndrome for 17 months since the commencement of cyclic rituximab therapy aimed at suppression of pathogenetic gamma heavy chains. Free light chains in serum and CD20-positive cells in peripheral blood were useful as hematological markers in the patient. Rituximab might be a potent therapeutic option for AH amyloidosis associated with a B-cell lymphoproliferative disorder.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1744-2818
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
178-80
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19590993-Amyloidosis,
pubmed-meshheading:19590993-Antibodies,
pubmed-meshheading:19590993-Antibodies, Monoclonal,
pubmed-meshheading:19590993-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:19590993-Antirheumatic Agents,
pubmed-meshheading:19590993-Female,
pubmed-meshheading:19590993-Humans,
pubmed-meshheading:19590993-Middle Aged,
pubmed-meshheading:19590993-Neoplasms, Plasma Cell,
pubmed-meshheading:19590993-Nephrotic Syndrome
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Rituximab therapy in nephrotic syndrome due to AH amyloidosis.
|
|
pubmed:publicationType |
Letter,
Case Reports,
Research Support, Non-U.S. Gov't
|
